Realising the promised gains of cardiovascular innovation will demand an increase in clinical cardiac decision-making capacity
Modern cardiovascular care has been blessed with therapeutic innovations that have reduced morbidity and mortality. From invasive management for acute coronary syndrome (ACS) to nurse-led heart failure management programs and anticoagulation for stroke prophylaxis in atrial fibrillation (AF), therapeutic advances have led not only to improved cardiovascular outcomes, but also the need for greater sophistication in balancing benefits with harms and costs (Box). With such complexity, decisions about management increasingly require access to risk stratification and evidence-based clinical decision support.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.